Company / Free Cash Flow
BioXcel Therapeutics, Inc. Free Cash Flow History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$57.6M
FY2025
5-year range
-$155.0M / -$57.6M
FY2022-FY2025
Trend
+62.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$58M.
Based on SEC 10-K filings.
-$58M in FY2025.
Improved from -$135M to -$58M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 62.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$57.6M | +62.8% |
| FY2024 | -$155.0M | -14.4% |
| FY2023 | -$135.5M | -64.0% |
| FY2022 | -$82.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026